Reports
Subscribe to
our newsletters!
Showing 37–48 of 65 resultsSorted by latest
-
on demand upon order placementThis competitive intelligence report about TSLP Inhibitors and TSLP Receptor Antagonists provides a competitor evaluation in the field of mostly antibodies targeting Thymic Stromal Lymphopoietin (TSLP) or its receptor as of...€ 300.00
-
June of 2025Landscape analysis of Vectorized antibodies by in vivo expression of DNA or RNA regarding stakeholders, R&D pipeline, profile & composition of drug candidates and business deals from an industry perspective...€ 2600.00
-
on demand upon order placementThis Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy as of March of 2025€ 500.00
-
March of 20252024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA€ 130.00
-
February of 2025Report with a landscape analysis of PD-(L)1 x VEGF(R) bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective...€ 2000.00
-
September of 2024Degrader-Antibody Conjugates 2024: Stakeholders, Technologies, Pipeline and Deals€ 2050.00
-
March of 20242023 sales data of originator therapeutic proteins and antibodies, selected biosimilars and other biologic drug modalities (gene & cell therapy, RNA)€ 130.00
-
August of 2023This report provides a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023Original price was: € 2150.00.€ 1720.00Current price is: € 1720.00.
-
March of 2023Sales data of originator therapeutic proteins and antibodies & selected biosimilar antibodies and proteins and other biologics in 2022€ 120.00
-
February of 2023This report provides a landscape description and analysis of CAR-M platform technologies and stakeholders from an industry perspective as of February 2023€ 1800.00
-
November of 2022This report provides a landscape description and analysis of discovery and development of novel drug modalities targeting RNA from an industry perspective as of November 2019.€ 2350.00
-
July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.Original price was: € 2550.00.€ 1800.00Current price is: € 1800.00.